{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-068020","form_type":"8-K","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2025-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.077977+00:00","generated_at":"2026-05-22T01:44:51.838425+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Athira Pharma Q1 net loss narrows to $9.1M; ATH-1105 Phase 1 complete, ALS dosing on track","bullets":["Cash, cash equivalents and investments totaled $36.7M as of March 31, 2025, down from $51.3M at year-end 2024.","Net loss for Q1 2025 was $9.1M ($0.23 per share) vs $26.3M ($0.69 per share) in Q1 2024.","R&D expenses fell to $4.3M from $21.2M, driven by fosgonimeton program cuts after failed LIFT-AD trial.","ATH-1105 Phase 1 healthy volunteer study completed; full data expected 2H25, ALS patient dosing to begin late 2025.","Company exploring strategic alternatives with Cantor Fitzgerald after discontinuing fosgonimeton development."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-068020","json":"https://secwatch.observer/filing/0000950170-25-068020.json","markdown":"https://secwatch.observer/filing/0000950170-25-068020.md","text":"https://secwatch.observer/filing/0000950170-25-068020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000095017025068020/0000950170-25-068020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000095017025068020/atha-20250509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T01:44:51.838425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}